the aid library

LIST OPTIONS

Filter

1047

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (152)

View PDF (135)

An economic investment case & financing requirements

ACT-Accelerator: An economic investment case & financing requirements (2021) C_WHO

This document lays out economic arguments for investing in the Access to COVID-19 Tools Accelerator (ACT-Accelerator). Framed within an overall context that recognizes the broader human health and societal impacts of the COVID-19 crisis, ACT-Accelerator's Economic Investment Case argues that investm... more

External Link

Epidemiology of Peripheral Artery Disease and Polyvascular Disease

Aday A.W.; Matsushita, K. Circulation Research (2021) CC

Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ... more

Download (144)

View PDF (148)

Building better immunity: A life course approach to healthy longevity

Pan American Health Organization PAHO (2023) C_WHO

As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt... more

Guidelines for Management of Type 1 Diabetes

Indian Council of Medical Research (2022) CC2

The ICMR type 1 diabetes guidelines come at a time when the SARS-CoV-2 pandemic has disproportionately affected people with diabetes population, exposing them to a high risk for severe illness and mortality. Globally, diabetes was responsible for over fourmillion deaths in the year 2019. It was th... more

Kenya Asthma Management Guideline

Ministry of Health (2021) CC

Bonchial asthma is the most common chronic respiratory disease in the world. In Kenya, it has been estimated that about 7.5% of the Kenyan population, nearly 4 million people, are currently living with asthma. Many cases tend to be underdiagnosed and undertreated which leads to high levels of morbid... more

Implications of the Marburg virus disease outbreak in Rwanda for the EU/EEA, 2024

European Centre for Disease Prevention and Control (ecdc) (2024) C_CDC

This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and, although uncommon, it has the potential to cause epidemics with significant case fatality. ... more

Targeted and selective strategies in measles and rubella vaccination campaigns: Interim guidance

World Health Organization WHO (2025) C_WHO

The World Health Organization provides regional and national strategies and operational plans that aim to support countries in work to achieve measles control and elimination. These are guided by high level frameworks including the Immunization Agenda 2030 and the Measles and Rubella Strategic Frame... more

External Link

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D.Y, et al. (2021) C1

Published:February 02, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00234-8

Download (254)

View PDF (396)

TIP 18: The Tuberculosis Epidemic: Legal and Ethical Issues for Alcohol and Other Drug Treatment Providers: Treatment Improvement Protocol (TIP) Series 18

D. H. Mulligan, U.S Department of health and human service (1995) C2

Download (809)

View PDF (1732)

Community Case Management of Malaria in Urban Settings

Mary Amuyunzu-Nyamongo WHO, TDR (2011)

A feasibility study in five African sites

Download (931)

View PDF (1530)

Malaria Case Management, Operations Manual

WHO (2009)

Download (1414)

View PDF (2316)

Manual of Basic Techniques for a Health Laboratory
recommended

World Health Organization WHO (2003) C_WHO

Download (1349)

View PDF (2422)

The Role of Laboratories and Blood Banks in Disaster Situations

Pan American Health Organization (2001) C_WHO

Download (1948)

View PDF (4091)

Polio Laboratory Manual

World Health Organization (2004) C_WHO

Download (1531)

View PDF (2917)

Specifications and quantities for efficient procurement of essential equipment and laboratory commodities for HIV

Francis Aboagye-Nyame, Heather Alexander, Zelalem Gizachew Belachew et al. World Health Organization (2015) C_WHO

Second Edition AIDS Medicines and diagnostics services July 2015

Guidance for national tuberculosis programmes on the management of tuberculosis in children

Stephen Graham, Malgosia Grzemska, Suzanne Hill et al World Health Organization WHO (2014) C_WHO

2nd edition. Like the original, this second edition of the guidance aims to inform the revision of existing national guidelines and standards for managing Tuberculosis (TB), many of which include guidance on children. It includes recommendations, based on the best available evidence, for improving ... more

Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings

World Health Organization WHO (1999) C_WHO

These guidelines are designed for settings with limited resources to provide inexpensive and effective control strategies for prevention of TB transmission in health care workers (HCW).

Download (1101)

View PDF (1513)

Core Set of Indicators & Indicator Data Sheets for Health and Social Health Protection

Deutsche Gesellschaft fü; r Internationale Zusammenarbeit (GIZ) GmbH ;; KfW (2012)

The Core Set of Indicators and respective Indicator Data Sheets aim to pave the way towards a common understanding, greater consistency and comparability across countries and alignment of results chains of German Development Cooperation in the field of health and social health protection with the in... more

Download (8743)

View PDF (2687)

Guide Material for Medical Store Management Training
recommended

Community Development Medicinal Unit (2012) C_WHO

Drugs and medical supplies are dispensed at the cutting edge level of the interface between the public health system and the people. Availability or lack of it brings either credit or discredit to the public health system. The primary reason for holding stocks of medicines and medical supplies in a ... more

Manual of Basic Techniques for a Health Laboratory recommended

Guide Material for Medical Store Management Training recommended

Manual of Basic Techniques for a Health Laboratory
recommended

Guide Material for Medical Store Management Training
recommended